Free Trial

CERo Therapeutics (CERO) Competitors

CERo Therapeutics logo
$8.67 -0.25 (-2.80%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$8.56 -0.11 (-1.21%)
As of 04:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CERO vs. NKGN, EDSA, SYBX, RLYB, IMNN, FLGC, ALVR, ERNA, ME, and NEUP

Should you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include NKGen Biotech (NKGN), Edesa Biotech (EDSA), Synlogic (SYBX), Rallybio (RLYB), Imunon (IMNN), Flora Growth (FLGC), AlloVir (ALVR), Ernexa Therapeutics (ERNA), 23andMe (ME), and Neuphoria Therapeutics (NEUP). These companies are all part of the "pharmaceutical products" industry.

CERo Therapeutics vs. Its Competitors

NKGen Biotech (NYSE:NKGN) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

CERo Therapeutics has a consensus target price of $45.00, indicating a potential upside of 419.03%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CERo Therapeutics is more favorable than NKGen Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CERo Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by company insiders. Comparatively, 12.7% of CERo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, CERo Therapeutics had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 1 mentions for CERo Therapeutics and 0 mentions for NKGen Biotech. CERo Therapeutics' average media sentiment score of 0.59 beat NKGen Biotech's score of 0.00 indicating that CERo Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
NKGen Biotech Neutral
CERo Therapeutics Positive

NKGen Biotech has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$2.45-0.13
CERo TherapeuticsN/AN/A-$8.30MN/AN/A

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
CERo Therapeutics N/A N/A -199.71%

Summary

CERo Therapeutics beats NKGen Biotech on 9 of the 11 factors compared between the two stocks.

Get CERo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CERO vs. The Competition

MetricCERo TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.44M$2.39B$5.47B$8.95B
Dividend YieldN/A1.80%5.25%4.06%
P/E RatioN/A8.9827.0020.10
Price / SalesN/A729.50428.95120.24
Price / CashN/A159.8036.8257.86
Price / Book-0.214.517.985.56
Net Income-$8.30M$31.26M$3.16B$248.40M
7 Day Performance-8.35%3.57%2.39%4.67%
1 Month Performance8.38%1.28%2.18%6.64%
1 Year Performance-97.77%1.08%33.82%21.31%

CERo Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CERO
CERo Therapeutics
3.6532 of 5 stars
$8.67
-2.8%
$45.00
+419.0%
-97.9%$3.44MN/A0.008
NKGN
NKGen Biotech
N/A$0.32
-3.5%
N/A-76.9%$14.32MN/A-0.06N/AGap Down
EDSA
Edesa Biotech
1.6697 of 5 stars
$2.03
flat
$5.00
+146.3%
-51.8%$14.25MN/A-1.2820News Coverage
SYBX
Synlogic
0.504 of 5 stars
$1.18
-7.1%
N/A-18.1%$13.81M$10K-0.4780
RLYB
Rallybio
2.732 of 5 stars
$0.33
-2.3%
$10.00
+2,927.6%
-60.7%$13.74M$640K-0.3040News Coverage
Gap Up
IMNN
Imunon
2.0476 of 5 stars
$0.78
-2.4%
$15.50
+1,884.1%
-46.0%$13.70M$500K-0.5730Gap Down
FLGC
Flora Growth
2.9896 of 5 stars
$0.60
+3.4%
$4.00
+566.7%
-34.2%$13.54M$59.51M-0.61280
ALVR
AlloVir
N/A$2.67
+1.9%
N/A-84.3%$13.47MN/A-0.13110
ERNA
Ernexa Therapeutics
0.6658 of 5 stars
$1.82
-1.1%
N/A-92.9%$13.40M$580K-0.2210News Coverage
ME
23andMe
N/A$0.50
-35.3%
N/A-94.2%$13.36M$208.78M-0.03770Gap Down
High Trading Volume
NEUP
Neuphoria Therapeutics
1.3041 of 5 stars
$7.02
-1.1%
$21.00
+199.1%
N/A$13.20M$10K0.00N/A

Related Companies and Tools


This page (NASDAQ:CERO) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners